Real world evidence of clinical predictors of glycaemic response to glucose‐lowering drugs among Chinese with type 2 diabetes
Diabetes/Metabolism Research and Reviews · 2023-05 · 39 (4)
DOI: 10.1002/dmrr.3615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 02.02.2023. Verfasst von Hongjiang Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Research Grants Council, University Grants Committee.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To examine whether simple clinical features can predict the 1‐year glycaemic response to glucose‐lowering drugs (GLDs) among Chinese with type 2 diabetes. Materials and Methods We used data from a diabetes risk assessment and complication screening programme and electronic medical records. We used linear regression models to examine the association between clinical features and 1‐year glycaemic response to GLDs.
Results
Use of metformin ( n = 15,433), sulphonylureas (SU) ( n = 15,190), dipeptidyl peptidase‐4 inhibitor (DPP‐4i) ( n = 7947), thiazolidinedione (TZD) ( n = 4107), and sodium‐glucose cotransporter 2 inhibitors (SGLT‐2i) ( n = 1883) were associated with a mean reduction of HbA1c ranging from 0.7% to 1.3% at one year. Men had a greater response to SU but a poorer response to metformin and TZD. Older age predicted a better response to all GLDs but not SGLT‐2i, whereas increasing diabetes duration was associated with a poorer response to all GLDs except for DPP‐4i. Obese patients responded greater to TZD and SGLT‐2i but poorer to SU than those with normal weight. Patients with a higher level of triglycerides to high‐density lipoprotein cholesterol ratio had a greater glycaemic response to TZD but a smaller response to SU and DPP‐4i.
Conclusions
Glycaemic response to GLDs differed considerably by clinical features among Chinese patients with type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
- Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, China.
- Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
- Hong Kong Hospital Authority, Hong Kong, China.
ORCID-Profile: Baoqi Fan, Ronald C W Ma, Juliana C N Chan, Andrea O Y Luk
Förderung
- Research Grants Council, University Grants Committee
Zitieren
APA
Wu, H., Lau, E. S. H., Yang, A., Fan, B., Ma, R. C. W., Kong, A. P. S., Chow, E., So, W. Y., Chan, J. C. N., & Luk, A. O. Y. (2023). Real world evidence of clinical predictors of glycaemic response to glucose‐lowering drugs among Chinese with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 39(4). https://doi.org/10.1002/dmrr.3615
Vancouver
Wu H, Lau ESH, Yang A, Fan B, Ma RCW, Kong APS, et al. Real world evidence of clinical predictors of glycaemic response to glucose‐lowering drugs among Chinese with type 2 diabetes. Diabetes/Metabolism Research and Reviews. 2023;39(4). doi:10.1002/dmrr.3615
BibTeX
@article{Wu2023,
author = {Wu, Hongjiang and Lau, Eric S H and Yang, Aimin and Fan, Baoqi and Ma, Ronald C W and Kong, Alice P S and Chow, Elaine and So, Wing-Yee and Chan, Juliana C N and Luk, Andrea O Y},
title = {Real world evidence of clinical predictors of glycaemic response to glucose‐lowering drugs among Chinese with type 2 diabetes},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2023},
volume = {39},
number = {4},
doi = {10.1002/dmrr.3615}
}
EUVIMED